Market Cap 150.68M
Revenue (ttm) 154.90M
Net Income (ttm) -20.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -13.04%
Debt to Equity Ratio 7.53
Volume 913,700
Avg Vol 1,739,618
Day's Range N/A - N/A
Shares Out 188.54M
Stochastic %K 46%
Beta 1.42
Analysts Strong Sell
Price Target $4.50

Company Profile

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed na...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 251 4400
Address:
100 Regency Forest Drive, Suite 300, Cary, United States
keypatience
keypatience Apr. 5 at 4:57 PM
$HRTX It’s on the website of Heron Therapeutic. Do you even read quarterly reports? https://ir.herontx.com/news-releases/news-release-details/heron-therapeutics-announces-fourth-quarter-and-full-year-2025
0 · Reply
keypatience
keypatience Apr. 5 at 4:07 PM
$HRTX Fully dedicated sales team, launched in Q3 2025, is gaining significant momentum in both expanding formulary access and driving successful utilization of APONVIE.
1 · Reply
keypatience
keypatience Apr. 5 at 4:05 PM
$HRTX “With a more powerful commercial engine, expanding demand signals, and improved reimbursement clarity, we believe Heron is well‑positioned for continued share gains and meaningful revenue expansion in 2026 and beyond.”
0 · Reply
keypatience
keypatience Apr. 3 at 7:30 PM
$HRTX "Adopting the Section 382 Rights Plan is intended solely to protect the significant potential value of the Company's NOLs, which we believe can offset pre-tax income as the Company executes its near-term and long-term organic and inorganic growth plan," said Adam Morgan, Board Chairman
0 · Reply
keypatience
keypatience Apr. 3 at 3:10 PM
0 · Reply
Sdwg
Sdwg Apr. 3 at 1:28 PM
$HRTX penny stocks with better looking charts $BLOZF, $EDIT, $PLUG....
0 · Reply
davidtmc
davidtmc Apr. 1 at 5:57 PM
$HRTX how long is the Syndicate going to allow this afternoon’s circle jerk to continue?
0 · Reply
Shooter40
Shooter40 Apr. 1 at 3:45 PM
$HRTX was yesterday the bottom? Time to start the steady climb to $5.00 a share by the end of this year! I still believe in CC even though he is not requiring all his senior staff to buy shares in the open market! 😡
0 · Reply
Highfade
Highfade Apr. 1 at 2:02 PM
$HRTX a little jab step to the .80s
0 · Reply
Tacto
Tacto Apr. 1 at 6:56 AM
$HRTX The link below is to a plan that expires on August 14th of this year. Perhaps it's Heron's convoluted version of a poison pill, to deter change of ownership? Interesting nonetheless. They clearly see it as a big deal https://herontherapeutics.gcs-web.com/static-files/f9ad021a-4679-46e3-b4d7-80ae5cf644c2 . .
0 · Reply
Latest News on HRTX
Heron: Near The Bottom Of A Trading Range Despite Positives

Feb 18, 2026, 10:28 AM EST - 6 weeks ago

Heron: Near The Bottom Of A Trading Range Despite Positives


Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:38 AM EDT - 11 months ago

Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript


U.S. District Court Upholds Validity of CINVANTI® Patents

Dec 3, 2024, 4:36 PM EST - 1 year ago

U.S. District Court Upholds Validity of CINVANTI® Patents


Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

Apr 16, 2024, 4:24 PM EDT - 2 years ago

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain


Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 10:35 PM EDT - 2 years ago

Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript


keypatience
keypatience Apr. 5 at 4:57 PM
$HRTX It’s on the website of Heron Therapeutic. Do you even read quarterly reports? https://ir.herontx.com/news-releases/news-release-details/heron-therapeutics-announces-fourth-quarter-and-full-year-2025
0 · Reply
keypatience
keypatience Apr. 5 at 4:07 PM
$HRTX Fully dedicated sales team, launched in Q3 2025, is gaining significant momentum in both expanding formulary access and driving successful utilization of APONVIE.
1 · Reply
keypatience
keypatience Apr. 5 at 4:05 PM
$HRTX “With a more powerful commercial engine, expanding demand signals, and improved reimbursement clarity, we believe Heron is well‑positioned for continued share gains and meaningful revenue expansion in 2026 and beyond.”
0 · Reply
keypatience
keypatience Apr. 3 at 7:30 PM
$HRTX "Adopting the Section 382 Rights Plan is intended solely to protect the significant potential value of the Company's NOLs, which we believe can offset pre-tax income as the Company executes its near-term and long-term organic and inorganic growth plan," said Adam Morgan, Board Chairman
0 · Reply
keypatience
keypatience Apr. 3 at 3:10 PM
0 · Reply
Sdwg
Sdwg Apr. 3 at 1:28 PM
$HRTX penny stocks with better looking charts $BLOZF, $EDIT, $PLUG....
0 · Reply
davidtmc
davidtmc Apr. 1 at 5:57 PM
$HRTX how long is the Syndicate going to allow this afternoon’s circle jerk to continue?
0 · Reply
Shooter40
Shooter40 Apr. 1 at 3:45 PM
$HRTX was yesterday the bottom? Time to start the steady climb to $5.00 a share by the end of this year! I still believe in CC even though he is not requiring all his senior staff to buy shares in the open market! 😡
0 · Reply
Highfade
Highfade Apr. 1 at 2:02 PM
$HRTX a little jab step to the .80s
0 · Reply
Tacto
Tacto Apr. 1 at 6:56 AM
$HRTX The link below is to a plan that expires on August 14th of this year. Perhaps it's Heron's convoluted version of a poison pill, to deter change of ownership? Interesting nonetheless. They clearly see it as a big deal https://herontherapeutics.gcs-web.com/static-files/f9ad021a-4679-46e3-b4d7-80ae5cf644c2 . .
0 · Reply
Tacto
Tacto Apr. 1 at 1:58 AM
$HRTX Today was the deadline for the crime syndicate operators to report standard short interest for the second half of March, thus the 5M change in availability in the shorting pool. If you never bothered to read 'Den of Thieves', the reason for such monster swings in the standard shorting pool is the result of just one of hundreds of their illegal activities that was revealed and detailed in the book. In this case, to evade reporting requirements, they rapidly swap it around among themselves at the reporting deadline, like a hot potato, and it's all about knowing exactly how the system works and employing precision timing to dodge those requirements. Additionally, because those who are supposed to be watchdogging this stuff are also members of the club, the standard shorting data is not made public for weeks after the reporting deadline, to ensure that any potential usefulness is completely negated . .
0 · Reply
keypatience
keypatience Mar. 31 at 8:48 PM
$HRTX Just one dollar up and I make a ridiculous amount of profit. It’s so easy to make money in our times.
1 · Reply
slayer2408
slayer2408 Mar. 31 at 7:57 PM
$HRTX a few more days like this and I’ll be green 💰
0 · Reply
ONLYPHARMS
ONLYPHARMS Mar. 31 at 6:48 PM
$HRTX People whine and cry because it goes down a few cents panel. We have a pretty decent day and crickets. Pretty funny.
3 · Reply
JAG_2_Trade
JAG_2_Trade Mar. 31 at 6:45 PM
$HRTX May God bless us more. Amen
0 · Reply
BullMaven
BullMaven Mar. 31 at 1:52 PM
$HRTX an update and insider buy will push this to 1.50
0 · Reply
BullMaven
BullMaven Mar. 31 at 1:38 PM
$HRTX we will get to 1+ soon. still will not sell a single share below 5+. no worry . insiders buy would definitely help
0 · Reply
keypatience
keypatience Mar. 31 at 12:42 PM
$HRTX Frankly speaking, some people here should never have invested in the biotech sector. It’s low-liquid, demands an iron stomach, and due diligence. They have absolute no patience for it.
0 · Reply
Braddog
Braddog Mar. 31 at 12:07 PM
$HRTX I wonder if we hold onto the $0.70s today? 😡😡😡😡😡😡😡😡😡😝😡
1 · Reply
Tacto
Tacto Mar. 30 at 10:55 PM
$HRTX The FUDsters are really cranking it up LOL But, this has nothing whatsoever to do with any of that stuff, rather it's simply a move by the crime syndicate operators to repeat their 2023 program, where they dunked it to half a dollar, then skyrocketed it for a 7-bagger. In order to accomplish their goal, they first had to thoroughly disassociate the stock from the company it's meant to represent, meaning that fundamentals currently have diddly squat to do with anything at all, so those who are full of crap really stand out here, like sore thumbs! Anyhow, the goons don't seem to be in a rush to bottom it, which tells us the harvesting is still in full swing, so we'll just continue scaling in, to ensure we're positioned for the mammoth windfall to come . .
1 · Reply
keypatience
keypatience Mar. 30 at 9:56 PM
$HRTX This can become a serious issue for next year if Heron underperforms. Mark my words.
0 · Reply
keypatience
keypatience Mar. 30 at 9:55 PM
$HRTX 2027 is likely the year investors really ask whether Heron can become an acute-care-led business before oncology weakens too much. It’s a game against the clock.
0 · Reply